How to buy Invex Therapeutics shares | A$0.96

Invex Therapeutics Ltd is a biotechnology business based in Australia. Invex Therapeutics shares (IXC) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.96 – an increase of 1.05% over the previous week. Invex Therapeutics has a trailing 12-month revenue of around $165,703.

How to buy shares in Invex Therapeutics

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Invex Therapeutics . Find the share by name or ticker symbol: IXC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Invex Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.96, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Invex Therapeutics . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Invex Therapeutics 's share price?

Since the stock market crash in March caused by coronavirus, Invex Therapeutics 's share price has had significant negative movement.

Its last market close was $0.96, which is 17.60% down on its pre-crash value of $1.165 and 81.13% up on the lowest point reached during the March crash when the shares fell as low as $0.53.

If you had bought $1,000 worth of Invex Therapeutics shares at the start of February 2020, those shares would have been worth $481.98 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $864.86.

Invex Therapeutics share price

Use our graph to track the performance of IXC stocks over time.

Invex Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-13.

Latest market close	AUDA$0.96
52-week range	AUDA$0.52 - AUDA$1.58
50-day moving average	AUDA$0.9697
200-day moving average	AUDA$1.1221
Target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.03

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Invex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Invex Therapeutics Ltd by TradingView

Invex Therapeutics price performance over time

Historical closes compared with the close of A$0.96 on 2020-10-20

1 week (2020-10-13)	-1.03%
1 month (2020-09-18)	-2.04%
3 months (2020-07-20)	-13.12%
6 months (2020-04-20)	-1.03%

1 year (2019-10-18)	74.55%
2 years (2018-10-16)	N/A
3 years (2017-10-16)	N/A
5 years (2015-10-16)	N/A

Invex Therapeutics financials

Revenue TTM	$165,703
Gross profit TTM	$165,703
Return on assets TTM	-10.47%
Return on equity TTM	-18.75%
Profit margin	0%
Book value	0.362
Market capitalisation	$56.4 million

TTM: trailing 12 months

Invex Therapeutics share dividends

We're not expecting Invex Therapeutics to pay a dividend over the next 12 months.

Invex Therapeutics overview

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.

Frequently asked questions

• What percentage of Invex Therapeutics is owned by insiders?

  Currently 83.77% of Invex Therapeutics shares are held by insiders.

• When does the fiscal year end for Invex Therapeutics ?

  Invex Therapeutics 's fiscal year ends in June.

• Where is Invex Therapeutics based?

  Invex Therapeutics 's address is: 38 Rowland Street, Subiaco, WA, Australia, 6008